Abstract: The present invention relates to a composition comprising a) an anionic compound having wetting and dispersing properties selected from the group of a1) an alkyl naphthalene sulfonate, a2) a naphthalene sulfonate-formaldehyde condensate that may optionally be alkyl substituted and mixtures thereof, and b) a nitrogen-containing surfactant selected from the group consisting of alkylamine alkoxylates, alkylamidoamine alkoxylates, alkanolamides and their alkoxylates, alkylamidopropylamines, betaines, amino acids, or any mixtures thereof, wherein <the weight ratio between a) and b) is between 99.99:0.01 and 40:60 while> the molar amount of anionic sulfonate and, if any are present, carboxylate groups in the composition is in excess of the molar amount of nitrogen-containing groups. These compositions exhibit synergistic wetting properties as compared to the surface-active components taken alone. Further, the compositions also exhibit an increased rainfastness.

Abstract: The invention is directed to a method of treating fibromyalgia syndrome in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof.

Abstract: A phospholipid extract from a marine or aquatic biomass possesses therapeutic properties. The phospholipid extract comprises a variety of phospholipids, fatty acid, metals and a novel flavonoid.

Abstract: Provided are compositions for repelling fluids comprising a volatile liquid carrier, a powder-feel agent and less than 5 weight % of an ester selected from the group consisting of formula I, formula II, formula III, and combinations of two or more thereof: wherein R1, R2, R3, R5, R6, R8 and R9 are independently linear or branched, substituted or unsubstituted, saturated or unsaturated, C3-C22 alkyl or alkenyl groups, R4 is a linear or branched, substituted or unsubstituted, saturated or unsaturated, C3-C22 alkylene or alkenylene moiety, and R7 is a linear or branched, substituted or unsubstituted, saturated or unsaturated C3-C22 moiety, the composition being substantially anhydrous. Also provided are methods of improving dryness and/or comfort associated with the intimate area, as well as, kits comprising the composition and an absorbent article.

Abstract: The object of the invention is to find the actions of the crude drugs contained in Daikenchuto or their components and the synergistic effect of the components with one another or with other pharmacologically active substances, and to provide new drugs or pharmaceutical compositions based on the findings. The invention is directed to intestinal peristaltic motility-enhancers comprising an effective amount of hydroxy-?-sanshool or a plant containing the same or an extract thereof; compositions comprising a combination of hydroxy-?-sanshool or a plant containing the same or an extract thereof and capsaicin or a plant containing the same or an extract thereof or bethanechol or a salt thereof; as well as a method for improving intestinal motility which comprises administering the composition to a patient.

Abstract: A body part is preserved using nitric oxide and/or a nitric oxide donor that does not directly release nitric oxide or a red blood cell nitrosylating agent, preferably ethyl nitrite to facilitate oxygen supply. A subject at risk for developing high altitude illness is administered a red blood nitrosylating agent in gaseous form that does not directly release nitric oxide, preferably ethyl nitrite.

Abstract: The invention relates to a cosmetic composition having a cooling effect, particularly a clear gel or a spray. The composition has a long-lasting cooling effect of about 8 hours and comprises a cooling complex consisting of 0.05-0.15% Menthyl Lactate, 0.1-0.2% Menthyl PCA and 0.05-0.2% Ethyl Menthane Carboxamide.

Abstract: This invention pertains generally to prostacyclin analogs and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. Generally, the compounds and methods of the present invention increase the oral bioavailability and circulating concentrations of treprostinil when administered orally.

Abstract: A pet food composition having at least two carotenoids. The carotenoids can include a keto-carotenoid and at least one non-keto-carotenoid. The keto-carotenoid can include astaxanthin. The keto-carotenoid can include astaxanthin ester. The non-keto-carotenoid can include beta-carotene and/or lutein.

Abstract: The present invention relates to antibacterial composition containing silver complexes, antibacterial treatment methods using the same and antibacterial formed article, in which the antibacterial composition containing silver complexes is economical, not wearing off due to washing, cleaning, rubbing, etc., firmly combined to improve durability and antibacterial effect, and applicable to various products due to great solubility and stability.

Abstract: A composition that provides a combination of bactericidal, fungicidal, insecticidal, hormonal and nutritional activity when treating plants in an effective amount. The composition is an aqueous ammonium salicylate, potassium salicylate, and potassium acetate solution consisting essentially of: a first reaction product of salicylic acid and ammonium hydroxide reacted in an aqueous media with ammonium hydroxide and further reacting with a second reaction product made by combining potassium acetate and potassium hydroxide. Urea and primary nutrients, secondary nutrients and micronutrients can be subsequently added to the composition.

Abstract: An oil-in-water emulsified sunscreen cosmetic which contains: (A) Containing the following three types of surfactants (A-1)-(A-3); (A-1) A POE stearic ester having a POE mole number of 20-120; (A-2) sorbitan tristearate; and (A-3) glyceryl stearate having a HLB of 5-8; (B) bis-ethylhexyloxyphenolmethoxyphenyltriazine and/or tert-butylmethoxybenzoylmethane, oil soluble ultraviolet absorbents, solid at room temperatures; (C) ethylhexyl methoxycinnamate and/or octocrylene, oil soluble ultraviolet absorbents, liquid at room temperature; (D) phenylbenzimidazolesulfonic acid, a water soluble ultraviolet absorbent; and (E) a higher alcohol having 14-24 carbon atoms.

Abstract: The present invention relates to lipid compounds of the general formula (I): wherein -n=0-2, —R1 and R2 are the same or different and may be selected from a group of substituents consisting of a hydrogen atom, an alkyl group, a halogen atom, and an alkoxy group; -, X is COR3 or CH2OR4, wherein —R3 is selected from the group consisting of hydrogen, hydroxy, alkoxy, and amino, —wherein X further comprises carboxylic acid derivatives when R3 is hydroxy and —R4 is selected from the group consisting of hydrogen, alkyl or acyl, —Y is a C9 to C21 alkene with one or more double bonds with E or Z configuration; or any pharmaceutically acceptable complex, solvate or pro-drug thereof. The present invention also relates to pharmaceutical compositions comprising such lipid compounds, and to such lipid compounds for use as medicaments or for diagnostic purposes.

Abstract: The present invention relates to salts of substituted allophanates, methods for their production, medicaments containing said compounds and the use of said compound for the production of medicaments.

Abstract: Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing physiologic functions, and are included in dilute concentrations in a balanced salt solution carrier.

Abstract: The present invention is directed to novel therapeutic compounds comprised of an amino acid bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. These high therapeutic index derivatives have the same utility as the drug from which they are made, and they have enhanced pharmacological and pharmaceutical properties. In fact, the novel drug derivatives of the present invention enhance at least one therapeutic quality, as defined herein. The present invention is also directed to pharmaceutical compositions containing same.

Abstract: A pesticidal composition containing: 4-methoxymethyl-2,3,5,6-tetrafluorobenzyl 3-(2-cyano-1-propenyl)-2,2-dimethylcyclopropanecarboxylate, a saturated hydrocarbon having an initial boiling point of 150 C or higher and a 95%-distillation temperature of 300 C or lower, and at least one alkyl carboxylate ester selected from the group consisting of the following esters (i) to (iii): (i) alkyl alkylcarboxylate esters having 12 to 20 carbon atoms, (ii) dialkyl dicarboxylate esters having 12 to 20 carbon atoms, and (iii) trialkyl acetylcitrate esters having 12 to 20 carbon atoms; has an excellent pesticidal activity.

Abstract: Use of polyunsaturated fatty acid derivatives as medicaments or functional foods. The present invention relates to the use of 1,2-fatty acid derivatives in the treatment or prevention of common diseases whose etiology is based on alterations (of any type) of the cell membrane lipids, for example, changes in levels, in the composition or in the structure of these lipids. In addition, for diseases in which the regulation of lipid composition and of the structure of the membranes (or proteins that interact with membranes) causes the reversion of pathological state.

Abstract: The present invention provides oral pravastatin formulations comprising a physical mixture of pravastatin and at least one pharmaceutically-acceptable excipient, wherein the composition for at least 6 months after its preparation is stable and has a pH of greater than about 7 to less than 9, as well as methods for the preparation and use of these stable formulations.

Abstract: The present invention concerns methods for treating and preventing renal/kidney disease, insulin resistance/diabetes, fatty liver disease, and/or endothelial dysfunction/cardiovascular disease using synthetic triterpenoids, optionally in combination with a second treatment or prophylaxis.

Abstract: The present invention describes a series of therapeutically active compounds of formula I, X—Y—Z??(I) that are useful for treating a disorder in a mammal. In the formula I, X and Z, which may be same or different, are independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclic group or substituted or unsubstituted heterocyclylalkyl; and Y is a linker selected from —O—, —S—, —NH—, —(CH2)n—, —CO—, —CONRa—, —NRaCO—, —NRaCOO—, —COO—, —CONRaCO—, —CONRaCOO— and —COOCOO—.

Abstract: The present invention relates to renin inhibitor compounds having the structure and their use in treating cardiovascular events and renal insufficiency.

Abstract: The present invention features a composition for killing fire ants. In some embodiments, the composition comprises an insecticide and a triclosan composition. In some embodiments, the composition is a liquid composition.

Abstract: The invention includes a method of increasing the substantivity of a personal care composition to hair, skin or nails by preparing a composition of an aqueous phase, a non-aqueous phase and a neutralized amino acid ester that is a reaction product of a neutral amino acid having a non-polar side chain with a long chain fatty alcohol and is represented by formula (I): wherein R1 is an alkyl group; R2 is a linear or branched carbon chain; and the amine group of the amino acid is neutralized with an acid. The composition is substantially free of petrochemicals and/or derivatives of petrochemical materials. The aqueous phase and the non-aqueous phase are emulsified by the neutralized amino acid ester. Other methods and an emulsifiers that is the neutralized amino acid ester are included. Because the neutralized amino acid ester and the compositions do not contain petrochemical-derived ingredient, the products are natural.

Abstract: Methods and compositions are provided for treating proliferative disorders, wherein the composition comprises at least one compound according to Formula I: wherein R1 is selected from the group consisting of —OH, —NH2, —NH—CH2—CO2H, —NH—CH(CH3)—CO2H, and —NH—C(CH3)2—CO2H, or a pharmaceutically acceptable salt of such a compound; and an anthracycline, e.g. doxorubicin, or a pharmaceutically acceptable salt thereof, or a platin, e.g. oxaliplatin, or a pharmaceutically acceptable salt thereof.

Abstract: A production method is provided for the preparation of small polymer microcapsules with an oil core and solid microspheres, containing high amounts of biocide by internal phase separation from emulsion droplets with ethyl acetate as a solvent. The size of the microcapsules and microspheres can be controlled with a high degree of accuracy between 0.2-20 micrometers in diameter. The microparticles are particularly well suited for coatings such as paints, lacquers and wood preservatives which are to be protected against microorganisms using biocides, as well as for surface protection directly, i.e. without combining the microparticles with a coating material.

Abstract: A method of preventing or treating diseases caused by Mycobacterium, comprising administering to a subject in need of such treatment an effective amount of a pleuromutilin.

Abstract: The present invention discloses certain novel prodrugs of florfenicol and/or of florfenicol analogs, including prodrugs of salts pharmaceutically acceptable salts of florfenicol and its analogs, including nitrogen-containing esters of the secondary alcohol group of florfenicol and of its analogs, and pharmaceutically acceptable salts thereof, compositions containing them, and methods of administering them to subjects. In particular embodiments the prodrugs are sufficiently water-soluble to serve the functions needed of a water-soluble prodrug of florfenicol or of a water-soluble prodrug of a florfenicol analog. A certain subclass of the compounds also possesses the hydrolytic stability needed to maintain the prodrug in solution in the subject's system until appropriate conditions exist when the prodrug can hydrolyze, releasing florfenicol or the florfenicol analog in question.

Abstract: The present invention relates to novel combinations of fatty acid derivatives and pyridine carboxy derivatives, including fatty acid esters with glycerol and 3-carboxy pyridine derivatives such as niacinamide. Such combinations have surprisingly shown antiviral and anti-microbial activity and the use for the treatment of inflammatory conditions and infections is disclosed herein.

Abstract: The present invention provides highly purified omega-3 fatty acid formulations. Certain formulations provided herein contain greater than 85% omega-3 fatty acids by weight. Certain other formulations provided herein contain EPA and DHA in a ratio of from about 4.01:1 to about 5:1. The invention also provides methods of using the dosage forms to treat a variety of cardiovascular, autoimmune, inflammatory, and central nervous system disorders by administering a formulation of the invention to a patient in need thereof.

Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of thyroid hormone, or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.

Abstract: The invention relates to an inhibitor of dimethylarginine dimethylaminohydrolase (DDAH) of general structural formula (I), wherein B is a branched or unbranched, substituted or non-substituted, saturated or unsaturated hydrocarbon chain having a chain length of 1 to 6 and/or a substituted or non-substituted aromatic system having a ring size of 3 to 6; R1 is selected from the group of structures (i-vii), wherein R2, R3 and R4 are selected from the group consisting of hydrogen, an alkyl or aryl radical, R5 and R6 are selected from the group consisting of hydrogen, a hydrocarbon chain having a chain length of 1 to 8 and an aryl radical, R7, R8, R9 and R10 are selected from the group consisting of hydrogen, and alkyl or aryl radical; W is oxygen (O) or nitrogen (N); and X is a methylene group (CH2) or a secondary amino group (NH); Y is a branched or unbranched, substituted or non-substituted, saturated or unsaturated hydrocarbon chain having a chain length of 1 to 6 and/or a substituted or non-substituted aromat

Abstract: A phospholipid extract from a marine or aquatic biomass possesses therapeutic properties. The phospholipid extract comprises a variety of phospholipids, fatty acid, metals and a novel flavonoid.

Abstract: A urinary anti-backflow device is provided which prevents urine from flowing back into the patient's bladder from a urine collection bag. The device comprises a flow tube having an upstream section connectable to an external urinary device secured to a patient and a downstream section connectable to a urine collection bag, a rod within the flow tube, and a stopper which moves along the rod between the downstream and upstream ends of the flow tube. When the upstream section of the flow tube is elevated relative to the downstream section, urine from the patient is free to flow through the flow tube. When the downstream section of the flow tube is elevated relative to the upstream section, urine forces the stopper against the upstream section to prevent backflow.

Abstract: Disclosed is a 2-methyl-2-pentenyl ester represented by the general formula (1) [wherein R represents a hydrogen atom or a hydrocarbon group having 1 to 9 carbon atoms which may have a substituent]. The compound has a new-type, unprecedented aroma and/or flavor, particularly a fruity, greenish or floral aroma and/or flavor. The compound can be added to a flavor or fragrance composition in an amount of 0.001 to 30 wt %. The flavor or fragrance composition can be added to a cosmetic product, a toiletry product, a bath agent, a food, a beverage or a pharmaceutical product in an amount of 0.0001 to 30 wt %. All of the compounds of the general formula (1) are novel, except for those compounds of the general formula (1) wherein R represents a methyl group, an isopropyl group, a phenyl group or a mesityl group.

Abstract: A compound, composition, method of synthesizing and using the compound of formula 1 are disclosed. The compound of formula I also comprises of salts, polymorphs, solvates, and hydrates thereof. The compound may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for peroral, topical, transmucosal, inhalation, targeted delivery and sustained release formulations. Such compositions may be used to treat hepatic and genetic disorders related to copper overload. Multiple other compounds may be added with the instant claimed compounds and may be delivered as a pharmaceutical dose suitable for treating Wilson's disease.

Abstract: The present invention relates to the use of acyl derivatives of curcumin, desmethoxy curcumin and bisdesmethoxy curcumin and of curcuminisoxazolide as components of animal feed or feed additives for the improvement of animal performance and the new acyl derivatives per se as well as the corresponding animal feed or feed additives containing them.

Abstract: Oral dosage forms with a high loading of 4-({[(2-methylpropanoyloxy)ethoxy]carbonylamino}methyl)cyclohexanecarboxylic acid are disclosed.

Abstract: A method of monitoring/controlling Thysanoptera (hereafter thrips) by the use of a behavior modifying compound of Formula (1), wherein Formula (1) is:— where R1 is a monoterpenyl group and R2 is a C3-C5 group.

Abstract: The present invention is directed to a method of treating disordered control of breathing including the treatment of apnea and hypoventilation associated with congenital or acquired brain stem abnormalities. Specifically the invention is directed to treating disordered control of breathing by administering an S-nitrosylating agent selected from the group consisting of ethylnitrite, glutathione, nitric oxide, S-nitrosocysteine, S-nitrosoglutathione, S-nitroso-L-cysteinyl glycine, N-acetyl cysteine and S-nitroso-N-acetyl cysteine. As shown in FIG. 1C the ability of endogenous SNOs to increase VE in freely behaving, conscious rats using whole-body plethysmography revealed that CSNO, GSNO and CGSNO (1 nmol each) caused equivalent increases in VE, whereas D-CSNO had no effect (left bar graph is the control whereas the right bar represents administration of the respective SNO).

Abstract: The present invention relates to hormone coating layers having desirable hormone delivery characteristics and product lifetime. In one embodiment, the invention is a hormone composition including a substrate having an external surface, and a coating layer disposed on the external surface. The coating layer preferably includes a polymer web, and from about 1 wppm to about 100,000 wppm of a hormone comprising a terpene dispersed throughout the polymer web. The invention also relates to methods for making hormone coating materials of the present invention. The coating compositions of the present invention preferably are implemented in human and animal food packaging materials in order to safely and efficiently protect the foodstuffs contained therein from insect infestation.

Abstract: Disclosed herein are novel compositions and methods for treating or preventing a variety of disorders and conditions associated with lipid metabolism. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more fibric acid or statin derivative compositions alone or in combination with one or more lipid altering agents and/or PDE inhibitors.

Abstract: Provided are compositions for repelling fluids comprising a volatile liquid carrier, a powder-feel agent and less than 5 weight % of an ester selected from the group consisting of formula I, formula II, formula III, and combinations of two or more thereof: wherein R1, R2, R3, R5, R6, R8 and R9 are independently linear or branched, substituted or unsubstituted, saturated or unsaturated, C3-C22 alkyl or alkenyl groups, R4 is a linear or branched, substituted or unsubstituted, saturated or unsaturated, C3-C22 alkylene or alkenylene moiety, and R7 is a linear or branched, substituted or unsubstituted, saturated or unsaturated C3-22 moiety, the composition being substantially anhydrous. Also provided are methods of improving dryness and/or comfort associated with the intimate area, as well as, kits comprising the composition and an absorbent article.

Abstract: Synergistic pesticidal mixtures are provided.

Abstract: Soil amendment compositions and methods for using the same are provided. The subject compositions are aqueous compositions consisting essentially of a carbon-skeleton energy component, a predisposing agent and a vitamin-cofactor component. The subject compositions find use in a variety of soil amendment applications, including: the control of soil born pests and pathogens; the improvement in soil fertility and/or characteristics, e.g. mineral release, water filtration; the neutralization and/or degradation of toxins, etc.

Abstract: The invention provides surface coating compositions comprising a preservative comprising 9-decenoic acid, salts of 9-decenoic acid, esters of 9-decenoic acid, or combinations thereof. The surface coating compositions may be water-based coatings (e.g., a latex paint) or solvent-based coatings (e.g., a solvent-based paint). The surface coating compositions may be paints, stains, varnishes, concrete coatings, anti-graffiti coatings, and the like. Methods for protecting a surface coating composition from in-can spoilage and protecting a coating of the surface coating composition from deterioration by the action of microorganisms are also described.

Abstract: Provided herein, inter alia, are solid forms of geldanamycin analogs, pharmaceutical compositions comprising a geldanamycin analog and a crystallization inhibitor, methods of making and using such compositions. Additionally, provided are methods for the treatment of cancer, a neoplastic disease state and/or a hyperproliferative disorder, and methods of inhibiting Heat Shock Protein 90 (“Hsp90”).

Abstract: A composition for attracting male Synanthedon scitula, containing a male Synanthedon scitula attracting effective amount of Z,Z-3,13-octadecadienyl acetate, optionally E,Z-2,13-octadecadienyl acetate, optionally Z,E-3,13-octadecadienyl acetate, and optionally a carrier material or carrier; the composition containing less than about 0.3% E,Z-3,13-octadecadienyl acetate based on the molar amount of the Z,Z-3,13-octadecadienyl acetate in the composition. A method for attracting male Synanthedon scitula to an object or area, involving treating an object or area with a male Synanthedon scitula attracting composition containing a male Synanthedon scitula attractant effective amount of Z,Z-3,13-octadecadienyl acetate, optionally E,Z-2,13-octadecadienyl acetate, optionally Z,E-3,13-octadecadienyl acetate, and optionally a carrier material or carrier; the composition containing less than about 0.3% E,Z-3,13-octadecadienyl acetate based on the molar amount of the Z,Z-3,13-octadecadienyl acetate in the composition.

Abstract: The present invention relates to the field of pain management, and more particularly to synergistic codrugs comprising an opioid and ketamine or norketamine which have been combined to form a single chemical codrug entity. When the codrug is administered it produces a synergistic analgesic response to pain.

Abstract: A dual thyrointegrin antagonist and a method for treating an angiogenesis-mediated disorder and/or a hyperthyroidism disorders by introducing the dual thyrointegrin antagonist into animals (e.g., mammals, human beings). The dual thyrointegrin antagonist includes a chemical structure having a thyroid hormone antagonist and ?v?3 integrin antagonist in the same molecule.